AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $408 thousand versus the consensus estimate of $80 thousand.

Earnings